


CLAIMS

1. A compound according to Formula II,



Formula II

wherein,

P is aryl;

if $m = 1$ then R^1 is attached to P at the meta position of the ring P relative to the attachment point of P to the 5-membered ring, and if $m = 2$ then R^1 is attached to P at the 2-, and 5-positions of the ring P to the 5-membered ring;

R^1 is selected from the group consisting of hydroxy, halo, nitro, C_{1-6} alkylhalo, OC_{1-6} alkylhalo, C_{1-6} alkyl, OC_{1-6} alkyl, C_{2-6} alkenyl, OC_{2-6} alkenyl, C_{2-6} alkynyl, OC_{2-6} alkynyl, C_{0-6} alkyl C_{3-6} cycloalkyl, OC_{0-6} alkyl C_{3-6} cycloalkyl, C_{0-6} alkylaryl, OC_{0-6} alkylaryl, CHO, $(CO)R^5$, $O(CO)R^5$, $O(CO)OR^5$, $O(CN)OR^5$, C_{1-6} alkyl OR^5 , OC_{2-6} alkyl OR^5 , C_{1-6} alkyl $(CO)R^5$, OC_{1-6} alkyl $(CO)R^5$, C_{0-6} alkyl CO_2R^5 , OC_{1-6} alkyl CO_2R^5 , C_{0-6} alkylcyano, OC_{2-6} alkylcyano, C_{0-6} alkyl NR^5R^6 , OC_{2-6} alkyl NR^5R^6 , C_{1-6} alkyl $(CO)NR^5R^6$, OC_{1-6} alkyl $(CO)NR^5R^6$, C_{0-6} alkyl $NR^5(CO)R^6$, OC_{2-6} alkyl $NR^5(CO)R^6$, C_{0-6} alkyl $NR^5(CO)NR^5R^6$, C_{0-6} alkyl SR^5 , OC_{2-6} alkyl SR^5 , C_{0-6} alkyl $(SO)R^5$, OC_{2-6} alkyl $(SO)R^5$, C_{0-6} alkyl SO_2R^5 , OC_{2-6} alkyl SO_2R^5 , C_{0-6} alkyl $(SO_2)NR^5R^6$, OC_{2-6} alkyl $(SO_2)NR^5R^6$, C_{0-6} alkyl $NR^5(SO_2)R^6$, OC_{2-6} alkyl $NR^5(SO_2)R^6$, C_{0-6} alkyl $NR^5(SO_2)NR^5R^6$, OC_{2-6} alkyl $NR^5(SO_2)NR^5R^6$, $(CO)NR^5R^6$, $O(CO)NR^5R^6$, NR^5OR^6 , C_{0-6} alkyl $NR^5(CO)OR^6$, OC_{2-6} alkyl $NR^5(CO)OR^6$, SO_3R^5 and a 5- or 6-membered ring containing atoms independently selected from the group consisting of C, N, O and S;

R^5 and R^6 are independently selected from a group consisting of hydrogen, C_{1-6} alkyl, C_{3-7} cycloalkyl and aryl;

X^1 and X^2 are independently selected from the group consisting of CR^4 , and N;

X³ is selected from the group consisting of CR⁴, N, and O; wherein at least one of X¹ X² and X³ is not N;

R⁴ is selected from the group consisting of H, =O, C₁₋₆alkyl, OH;

R³ is selected from the group consisting of H, C₁₋₆alkyl, hydroxy, C₀₋₆alkylcyano, oxo, =NR⁵, =NOR⁵, C₁₋₄alkylhalo, halo, C₃₋₇cycloalkyl, O(CO)C₁₋₄alkyl, C₁₋₄alkyl(SO)C₀₋₄alkyl, C₁₋₄alkyl(SO₂)C₀₋₄alkyl, (SO)C₀₋₄alkyl, (SO₂)C₀₋₄alkyl, OC₁₋₄alkyl, C₁₋₄alkylOR⁵ and C₀₋₄alkylNR⁵R⁶;

X^4 is selected from the group consisting of CR^7R^8 , NR^7 , O, S, SO, and SO_2 ;

R⁷ and R⁸ are independently selected from a group consisting of hydrogen, C₁₋₆alkyl, C₃₋₇cycloalkyl and aryl;

X⁵ and X⁶ are independently selected from the group consisting of C, N, O and S;

R² is selected from the group consisting of hydroxy, C₀₋₆alkylcyano, =NR⁵, =NOR⁵, C₁₋₄alkylhalo, halo, C₁₋₆alkyl, C₃₋₆cycloalkyl, C₀₋₆alkylaryl, C₀₋,

$$\text{6alkylheteroaryl, C}_{0-6}\text{alkylcycloalkyl, C}_{0-6}\text{alkylheterocycloalkyl, OC}_{1-4}\text{alkyl, OC}_{0-}$$

6alkylaryl, O(CO)C₁₋₄alkyl, (CO)OC₁₋₄alkyl, C₀₋₄alkyl(S)C₀₋₄alkyl, C₁₋₄alkyl(SO)C₀₋₄alkyl, C₁₋₄alkyl(SO₂)C₀₋₄alkyl, (SO)C₀₋₄alkyl, (SO₂)C₀₋₄alkyl, C₁₋₄alkylOR⁵, C₀₋₄alkylNR⁵R⁶ and a 5- or 6-membered ring containing atoms independently selected from C, N, O and S, and wherein said ring may be substituted by one or more A; and

any C₁₋₆alkyl, aryl or heteroaryl defined under R¹, R² and R³ may be substituted by one or more A;

A is selected from the group consisting of hydrogen, hydroxy, halo, nitro, oxo, C₀-₆alkylcyano, C₀₋₄alkylC₃₋₆cycloalkyl, C₁₋₆alkyl, C₁₋₆alkylhalo, OC₁₋₆alkylhalo, C₂₋₆alkenyl, C₀₋₃alkylaryl, C₀₋₆alkylOR⁵, OC₂₋₆alkylOR⁵, C₁₋₆alkylSR⁵, OC₂₋₆alkylSR⁵, (CO)R⁵, O(CO)R⁵, OC₂₋₆alkylcyano, OC₁₋₆alkylCO₂R⁵, O(CO)OR⁵, OC₁₋₆alkyl(CO)R⁵, C₁₋₆alkyl(CO)R⁵, NR⁵OR⁶, C₁₋₆alkylNR⁵R⁶, OC₂₋₆alkylNR⁵R⁶, C₀₋₆alkyl(CO)NR⁵R⁶, OC₁₋₆alkyl(CO)NR⁵R⁶, OC₂₋₆alkylNR⁵(CO)R⁶, C₀₋₆alkylNR⁵(CO)R⁶, C₀₋₆alkylNR⁵(CO)NR⁵R⁶, O(CO)NR⁵R⁶, C₀₋₆alkyl(SO₂)NR⁵R⁶, OC₂₋₆alkyl(SO₂)NR⁵R⁶, C₀₋₆alkylNR⁵(SO₂)R⁶, OC₂₋₆alkylNR⁵(SO₂)R⁶, SO₃R⁵, C₁₋₆alkylNR⁵(SO₂)NR⁵R⁶, OC₂₋₆alkyl(SO₂)R⁵, C₀-

$_{6\text{alkyl}}(\text{SO}_2)\text{R}^5$, $\text{C}_{0-6}\text{alkyl}(\text{SO})\text{R}^5$, $\text{OC}_{2-6}\text{alkyl}(\text{SO})\text{R}^5$ and a 5- or 6-membered ring containing one or more atoms independently selected from the group consisting of C, N, O and S;

m is selected from 1 and 2;

n is selected from 0, 1, 2, 3 and 4;

p is selected from 1 and 2; and

and a salts or hydrates thereof,

2. A compound according to claim 1 wherein P is phenyl.

3. A compound according to claim 1 wherein X^4 is selected from CR^7R^8 , NR^7 , O and S.

4. A compound according to claim 1 wherein X^5 is N.

5. A compound according to claim 4 wherein X^6 is N.

6. A compound according to claim 4 wherein X^6 is O.


7. A compounds according to claim 1 wherein X^5 is C and X^6 is N.

8. A compound according to claim 1 wherein R^2 is selected from aryl and $\text{C}_{0-6}\text{heteroaryl}$

9. A compound according to claim 1 wherein R^2 is selected from 4-pyridyl, 3-pyridyl and phenyl.

10. A compound according to claim 1 wherein R^2 is a 5- or 6-membered ring containing atoms independently selected from C, N, O and S, which ring may be substituted by one or more A.

11. A compound according to claim 1 wherein the ring containing X^1 , X^2 , and X^3 is selected from the group consisting of:



12. A compound according to claim 1 wherein X^1 and X^2 are N and X^3 is C.

13. A compound according to claim 1 selected from the group consisting of:

3-(3-chlorophenyl)-5-[[4-methyl-5-pyridin-3-yl-4H-1,2,4-triazol-3-yl]thio]methyl}-1,3,4-oxadiazol-2(3H)-one

2-(3-chlorophenyl)-5-{1-[methyl(4-methyl-5-pyridin-4-yl-4H-1,2,4-triazol-3-yl)amino]ethyl}-2,4-dihydro-3H-1,2,4-triazol-3-one

5 4-(5-{1-[1-(3-chlorophenyl)-1H-pyrazol-4-yl]ethoxy}-4-methyl-4H-1,2,4-triazol-3-yl)pyridine

4-(5-{1-[2-(3-chlorophenyl)-2H-1,2,3-triazol-4-yl]ethoxy}-4-methyl-4H-1,2,4-triazol-3-yl)pyridine

10 4-[5-({1-[2-(3-chlorophenyl)-2H-1,2,3-triazol-4-yl]ethyl}thio)-4-cyclopropyl-4H-1,2,4-triazol-3-yl]pyridine

4-{5-[1-(3-Chloro-phenyl)-1H-[1,2,4]triazol-3-ylmethylsulfanyl]-4-cyclopropyl-4H-[1,2,4]triazol-3-yl}-pyridine

4-{5-[1-(3-Chloro-phenyl)-1H-[1,2,4]triazol-3-ylmethoxy]-4-cyclopropyl-4H-[1,2,4]triazol-3-yl}-pyridine

15 4-{5-[1-(3-Chloro-phenyl)-1H-[1,2,3]triazol-4-ylmethylsulfanyl]-4-methyl-4H-[1,2,4]triazol-3-yl}-pyridine

4-{5-[1-(3-Chloro-phenyl)-1H-[1,2,3]triazol-4-ylmethylsulfanyl]-4-cyclopropyl-4H-[1,2,4]triazol-3-yl}-pyridine

20 4-{5-[1-(3-Chloro-phenyl)-1H-[1,2,3]triazol-4-ylmethoxy]-4-cyclopropyl-4H-[1,2,4]triazol-3-yl}-pyridine, and

4-(5-((1*R*)-[2-(3-chlorophenyl)-2*H*-1,2,3-triazol-4-yl]ethoxy)-4-methyl-4*H*-1,2,4-triazol-3-yl)pyridine

14. A pharmaceutical composition comprising as active ingredient a therapeutically effective amount of the compound according to any one of claims 1 to 13, in association
25 with one or more pharmaceutically acceptable diluent, excipients and/or inert carrier.

15. The pharmaceutical composition according to claim 14, for use in the treatment of mGluR 5 mediated disorders.

16. The compound according to any one of claims 1 to 13, for use in therapy.

17. The compound according to any one of claims 1 to 13, for use in treatment of mGluR 5 mediated disorders.

18. Use of the compound according to any one of claims 1 to 13, in the manufacture of a medicament for the treatment of mGluR 5 mediated disorders.

5 19. A method of treatment of mGluR 5 mediated disorders, comprising administering to a mammal, including man in need of such treatment, a therapeutically effective amount of the compound according to any one of claims 1 to 13.

20. The method according to claim 19, for use in treatment of neurological disorders.

21. The method according to claim 19, for use in treatment of psychiatric disorders.

10 22. The method according to claim 19, for use in treatment of chronic and acute pain disorders.

23. The method according to claim 19, for use in treatment of gastrointestinal disorders.

24. A method for inhibiting activation of mGluR 5 receptors, comprising treating a cell containing said receptor with an effective amount of the compound according to claim 1.